| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medical Informatics |
| Manuscript Type |
Observational Study |
| Article Title |
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jiang-Hua Zhou, Bin Wu, Wen-Xin Wang, Fang Lei, Xu Cheng, Juan-Juan Qin, Jing-Jing Cai, Xiao‐Jing Zhang, Feng Zhou, Ye-Mao Liu, Hao-Miao Li, Li-Hua Zhu, Zhi‐Gang She, Xin Zhang, Juan Yang and Hong-Liang Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key R&D Program of China |
2019YFC2004702 |
| National Key R&D Program of China |
2020YFC0845500 |
| the National Science Foundation of China |
81970070 |
| the National Science Foundation of China |
81970011 |
| the Hubei Science and Technology Support Project |
2019BFC582 |
| the Hubei Science and Technology Support Project |
2018BEC473 |
|
| Corresponding Author |
Hong-Liang Li, MD, PhD, Professor, Department of Cardiology, Renmin Hospital of Wuhan University; Institute of Model Animal of Wuhan University, No. 115 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. lihl@whu.edu.cn |
| Key Words |
COVID-19; SARS-CoV-2; DPP4 inhibitors; Diabetes; Glucose-control; Adverse effects |
| Core Tip |
Our study illuminated that there were no significant associations between in-hospital use of dipeptidyl peptidase-4 (DPP4) inhibitor (DPP4i) and 28-d all-cause mortality or multiorgan injury. In addition, the glucose control effects, inflammatory response, and associated adverse events were also comparable between patients in the DPP4i group and non-DPP4i group. These data provided direct clinical evidence to support the continuation of DPP4i therapy in diabetic patients with coronavirus disease 2019 (COVID-19). Moreover, this work paves the way for prospective studies and randomized controlled clinical trials on DPP4 inhibitor therapy for COVID-19. |
| Publish Date |
2020-11-25 14:44 |
| Citation |
Zhou JH, Wu B, Wang WX, Lei F, Cheng X, Qin JJ, Cai JJ, Zhang X, Zhou F, Liu YM, Li HM, Zhu LH, She Z, Zhang X, Yang J, Li HL. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases 2020; 8(22): 5576-5588 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i22/5576.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i22.5576 |
